Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 80

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 9
Chunk 80
---
 be
filed with the Securities and Exchange Commission in connection with the Annual Meeting of Stockholders to be held in 2025 (the “2025
Proxy Statement”), under the heading “Election of Directors.”

ITEM
11. EXECUTIVE COMPENSATION

The
information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement under the heading
“Executive Compensation.”

ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The
information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement under the headings
“Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.”

ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The
information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement under the headings
“Family Relationships and other Arrangements.”

ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The
information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement under the heading
“Proposal 2: Ratification of the Appointment of Our Independent Registered Public Accounting Firm for Fiscal Year Ending December
31, 2025.”

-36-

PART
IV

ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a)
The following documents are filed as part of this report:

    (1)
    Financial
    Statements:

    Page
  
    Index to Consolidated Financial Statements:
    F-1

    Consolidated
    Financial Statements:

    Report of the Independent Registered Public Accounting Firm
    F-2
  
    Consolidated Balance Sheets as of December 31, 2024 and 2023
    F-3
  
    Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023
    F-4
  
    Consolidated Statements of Changes in Stockholders’ Equity for the Years ended December 31, 2024 and 2023
    F-5
  
    Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023
    F-6
  
    Notes to the Consolidated Financial Statements
    F-7

The
consolidated financial statements required by this Item are included beginning at page F-1